SCHEMBL756325

SCHEMBL756325

Cc1ccccc1C(=O)Nc1ccn(Cc2cc(Cl)ccc2C(F)(F)F)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
PTGER1 P34995 2/20 0.49
RIPK1 Q13546 3/20 0.49
STIM1 Q13586 2/20 0.48
ORAI1 Q96D31 2/20 0.48
ORAI3 Q9BRQ5 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
MAPT P10636 3/20 0.47
KDM4E B2RXH2 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
HTT P42858 2/20 0.47
APP P05067 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
SNCA P37840 1/20 0.47
ALDH1A1 P00352 2/20 0.46
USP2 O75604 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL757550 0.92 STIM1 (0.55) LMNAPTGER1RIPK1STIM1ORAI1
SCHEMBL755458 0.90 KDM4E (0.54) LMNAPTGER1RIPK1STIM1ORAI1
SCHEMBL759178 0.89 STIM1 (0.56) LMNAPTGER1STIM1ORAI1ORAI3
SCHEMBL759098 0.88 NPSR1 (0.54) LMNARIPK1STIM1ORAI1ORAI3
SCHEMBL756922 0.84 STIM1 (0.59) LMNAPTGER1STIM1ORAI1ORAI3
SCHEMBL758395 0.83 STIM1 (0.55) LMNARIPK1STIM1ORAI1ORAI3
SCHEMBL758509 0.82 STIM1 (0.57) LMNAPTGER1RIPK1STIM1ORAI1
SCHEMBL755374 0.82 STIM1 (0.71) LMNAPTGER1STIM1ORAI1ORAI3
SCHEMBL758182 0.82 STIM1 (0.64) LMNAPTGER1STIM1ORAI1ORAI3
SCHEMBL756222 0.82 STIM1 (0.58) LMNARIPK1STIM1ORAI1ORAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399436-B2 N-pyrazolyl carboxamides as CRAC channel inhibitors GLAXO GROUP LIMITED (GB) 2013-03-19 US disclosed
US-8399436-B2 N-pyrazolyl carboxamides as CRAC channel inhibitors GLAXO GROUP LIMITED (GB) 2013-03-19 US disclosed
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-01 US disclosed
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-01 US disclosed
WO-2010122089-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS GLAXO GROUP LIMITED (GB) 2010-10-28 WO disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 US disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 US disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS ORAI1, TRPV1, CACNA1E LMNA 857/4885PTGER1 627/4885RIPK1 637/4885
US-20100273744-A1 COMPOUNDS LTC4S, HRH4, HRH2 LMNA 4198/4885PTGER1 247/4885RIPK1 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.